ReviewCells2022
The Complex Relation between Atrial Cardiomyopathy and Thrombogenesis.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- CD8Nature reviews. Cardiology · 2026Review
- Multi-modal tissue-aware graph neural network forbioRxiv : the preprint server for biology · 2026Article
- Cellular and molecular cross-talk in atrial fibrillation: The role of non-cardiomyocytes in creating an arrhythmogenic substrate.The Journal of physiology · 2026Review
- Diabetic Atrial Cardiomyopathy: Pathogenesis, Diagnosis, Management, AI-Driven Diagnosis, and Risk Prediction.Journal of diabetes research · 2026Review
- Renal Function, Atrial Cardiopathy, and Their Joint Association with Mortality in the General Population.Journal of clinical medicine · 2025Article
- Atrial cardiomyopathy: current clinical perspectives and future insights.Future cardiology · 2025Review
- Interatrial Block as a Common Finding in Patients with Acute Pulmonary Artery Embolism.Journal of clinical medicine · 2025Article
- Stem cell-derived heterocellular atrial engineered cardiac tissue with comparisons to native human atrial myocardium.American journal of physiology. Heart and circulatory physiology · 2025Article
- Atrial Cardiopathy Worsens Neurological Severity, Raises Recurrence Rates, and Leads to Poor Vascular Outcomes in Patients With Embolic Stroke of Undetermined Source.Journal of stroke · 2025Article
- Maintenance and Reversibility of Paroxysmal Atrial Fibrillation in JDP2 Overexpressing Mice.Cells · 2025Article
- Cardiac Magnetic Resonance in the Assessment of Atrial Cardiomyopathy and Pulmonary Vein Isolation Planning for Atrial Fibrillation.Journal of imaging · 2025Review
- Immune Regulation in Atrial Cardiomyopathy.Reviews in cardiovascular medicine · 2025Review
- Constitutive deletion of the obscurin-Ig58/59 domains induces atrial remodeling and Ca2+-based arrhythmogenesis.JCI insight · 2025Article
- The correlation between left atrial appendage morphology and thromboembolic risk in atrial fibrillation.Frontiers in stroke · 2025Review
- Role of STK38L in atrial fibrillation-associated myocardial fibrosis: findings from RNA-seq analysis.Cardiovascular diagnosis and therapy · 2024Article
- Rivaroxaban versus enoxaparin plus clopidogrel therapy for hypertrophic cardiomyopathy-associated thromboembolism in cats.Veterinary world · 2024Article
- Clinical value of artificial intelligence 3D echocardiography in evaluating left atrial volume and pulmonary vein structure in patients with atrial fibrillation.Clinics (Sao Paulo, Brazil) · 2024Article
- Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart disease, as well as systemic metabolic alterations, can leave a 'fingerprint' of structural and functional changes in the atrial myocardium, leading to the onset of atrial cardiomyopathy. As demonstrated in various animal models, some of these changes, such as fibrosis, cardiomyocyte hypertrophy and fatty infiltration, can increase vulnerability to atrial fibrillation (AF), the most relevant manifestation of atrial cardiomyopathy in clinical practice. Atrial cardiomyopathy accompanying AF is associated with thromboembolic events, such as stroke. The interaction between AF and stroke appears to be far more complicated than initially believed. AF and stroke share many risk factors whose underlying pathological processes can reinforce the development and progression of both cardiovascular conditions. In this review, we summarize the main mechanisms by which atrial cardiomyopathy, preceding AF, supports thrombogenic events within the atrial cavity and myocardial interstitial space. Moreover, we report the pleiotropic effects of activated coagulation factors on atrial remodeling, which may aggravate atrial cardiomyopathy. Finally, we address the complex association between AF and stroke, which can be explained by a multidirectional causal relation between atrial cardiomyopathy and hypercoagulability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.